Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.

Abstract

We examined the rates of malignancy at 2 yr after transplantation in renal allograft patients receiving sirolimus (SRL) in continuous combination with cyclosporine (CsA), SRL as base therapy or SRL maintenance therapy after early withdrawal of CsA. A total of 1295 patients were enrolled in two double-blind studies comparing SRL with azathioprine (AZA) or… (More)

Topics

Cite this paper

@article{Mathew2004TwoyearIO, title={Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.}, author={Timothy Hamish Mathew and Henri A Kreis and Peter John Friend}, journal={Clinical transplantation}, year={2004}, volume={18 4}, pages={446-9} }